Deucravacitinib (Sotyktu®). HTA ID: 23030

Assessment Status Rapid Review Complete
HTA ID 23030
Drug Deucravacitinib
Brand Sotyktu®
Indication Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 01/06/2023
Rapid review completed 27/06/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that deucravacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.